Contribution of epigenetic alteration of BRCA1 and BRCA2 genes in breast carcinomas in Tunisian patients

[en] Objective: The aim of this study was to evaluate the contribution of the BRCA1 and BRCA2 promoter methylation in the pathogenesis of sporadic breast cancer in Tunisian patients. Methods: Breast carcinoma tissues (n=117) and available paired normal breast tissues (n=65) from Tunisian women who had no family history were investigated for the methylation status of BRCA1 and BRCA2 promoters using methylation-specific PCR. Breast specimens from women without carcinoma (16 fibroadenomas and 5 mastopathies) were used as control. Results: Hypermethylation of BRCA1 and BRCA2 promoters was detected respectively in 60.7% and 69.2% of the carcinoma tissues, and in only 7.7% and 4.6% of the paired normal breast tissues. None of the fibroadenomas and mastopathies showed hypermethylation. Correlations were found between BRCA1 and BRCA2 hypermethylation and decrease in their mRNA expression (p=0.02 and p=0.009, respectively). Moreover, BRCA1 methylation correlates with patients age (p=0.01) and triple negative (ER-, PR-, HER2-) tumors (p=0.01). Patients with methylated BRCA1 and/or BRCA2 had a significant prolonged survivals compared to those with unmethylated tumors (p=0.002). Conclusion: Our results suggest an important role of BRCA1 and BRCA2 promoter methylation in breast cancer development in the Tunisian population.

Disciplines :

Oncology

Author, co-author :

Ben Gacem, Riadh

Hachana, Mohamed Ridha ; Université de Liège - ULiège > Département des sciences cliniques > GIGA-R:Immunopath. - Maladies infect. et médec. inter. gén.

Ziadi, Sonia

Amara, Khaled

Korbi, Sadok

Trimeche, Mounir

Language :

English

Title :

Contribution of epigenetic alteration of BRCA1 and BRCA2 genes in breast carcinomas in Tunisian patients

Publication date :

04 October 2011

Journal title :

Cancer Epidemiology, Biomarkers and Prevention

ISSN :

1055-9965

eISSN :

1538-7755

Publisher :

American Association for Cancer Research, Inc. (AACR), Birmingham, United States - Alabama

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 23 March 2011

Statistics

Number of views

126 (8 by ULiège)

Number of downloads

3 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Ferlay J., Bray F., Pisani P., Parkin D.M. GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide, IARC CancerBase No. 5, version 2.0 2000, IARC Press, Lyon.
Parkin D.M., Ferlay J., Hamdi-Cherif M., Sitas F., Thomas J.O., Wabinga H., et al. Cancer in Africa: epidemiology and prevention 2003, IARC Press, Lyon.
Arver B., Du Q., Chen J., Luo L., Lindblom A. Hereditary breast cancer: a review. Semin Cancer Biol 2000, 10:271-288.
Miki Y., Swensen J., Shattuck-Eidens D., Futreal P.A., Harshman K., Tavtigian S., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266:66-71.
Friedman L.S., Ostermeyer E.A., Szabo C.I., Dowd P., Lynch E.D., Rowell S.E., et al. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 1994, 8:399-404.
Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378:789-792.
Lux M.P., Fasching P.A., Beckmann M.W. Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med 2006, 84:16-28.
Futreal P.A., Liu Q., Shattuck-Eidens D., Cochran C., Harshman K., Tavtigian S., et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994, 266:120-122.
Khoo U.S., Ozcelik H., Cheung A.N., Chow L.W., Ngan H.Y., Done S.J., et al. Somatic mutations in the BRCA1 gene in Chinese sporadic breast and ovarian cancer. Oncogene 1999, 18:4643-4646.
Cleton-Jansen A.M., Collins N., Lakhani S.R., Weissenbach J., Devilee P., Cornelisse C.J., et al. Loss of heterozygosity in sporadic breast tumours at the BRCA2 locus on chromosome 13q12-q13. Br J Cancer 1995, 72:1241-1244.
Schmutzler R.K., Bierhoff E., Werkhausen T., Fimmers R., Speiser P., Kubista E., et al. Genomic deletions in the BRCA1, BRCA2 and TP53 regions associate with low expression of the estrogen receptor in sporadic breast carcinoma. Int J Cancer 1997, 74:322-325.
Baylin S.B., Herman J.G. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000, 16:168-174.
Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3:415-428.
Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002, 21:5427-5440.
Catteau A., Morris J.R. BRCA1 methylation: a significant role in tumor development?. Cancer Biol 2002, 12:359-371.
Rice J.C., Massey Brown K.S., Futscher B.W. Aberrant methylation of BRCA1 CpG island is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene 1998, 17:1807-1812.
Esteller M., Silva J.M., Dominguez G., Bonilla F., Matias-Guiu X., Lerma E., et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000, 92:564-569.
Hilton J.L., Geisler J.P., Rathe J.A., Hattermann-Zogg M.A., De Young B., Buller R.E. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 2002, 94:1396-1406.
Collins N., Wooster R., Stratton M.R. Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers. Br J Cancer 1997, 76:1150-1156.
Maalej M., Frikha H., Ben Salem S., Daoud J., Bouaouina N., Ben Abdallah M., et al. Breast cancer in Tunisia: clinical and epidemiological study. Bull Cancer 1999, 86:302-306.
Ben Ahmed S., Aloulou S., Bibi M., Landolsi A., Nouira M., Ben Fatma L., et al. Breast cancer prognosis in Tunisian women: analysis of a hospital series of 729 patients. Sante Publique 2004, 14:231-241.
Hachana M., Trimeche M., Ziadi S., Amara K., Korbi S. Evidence for a role of the Simian Virus 40 in human breast carcinomas. Breast Cancer Res Treat 2009, 113:43-58.
Charef-Hamza S., Trimeche M., Ziadi S., Amara K., Gaddas N., Mokni M., et al. Loss of heterozygosity at the BRCA1 locus in Tunisian women with sporadic breast cancer. Cancer Lett 2005, 224:185-191.
Saiki R.K., Bugawan T.L., Horn G.T., Mullis K.B., Erlich H.A. Analysis of enzymatically amplified beta-globin and HLA-DQ alpha DNA with allele-specific oligonucleotide probes. Nature 1986, 324:163-166.
Singal R., Ferdinand L., Reis I.M., Schlesselman J.J. Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease. Oncol Rep 2004, 12:631-637.
Gras E., Cortes J., Diez O., Alonso C., Matias-Guiu X., Baiget M., et al. Loss of heterozygosity on chromosome 13q12-q14, BRCA-2 mutations and lack of BRCA-2 promoter hypermethylation in sporadic epithelial ovarian tumors. Cancer 2001, 92:787-795.
Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. PNAS 1996, 93:9821-9826.
Miyamoto K., Fukutomi T., Asada K., Wakazono K., Tsuda H., Asahara T., et al. Promoter hypermethylation and post-transcriptional mechanisms for reduced BRCA1 immunoreactivity in sporadic human breast cancers. Jpn J Clin Oncol 2002, 32:79-84.
Tripathi M.K., Misra S., Khedkar S.V., Hamilton N., Irvin-Wilson C., Sharan C., et al. Regulation of BRCA2 gene expression by the SLUG repressor protein in human breast cells. J Biol Chem 2005, 280:17163-17171.
Baranovskaya S., Soto J.L., Perucho M., Malkhosyan S.R. Functional significance of concomitant inactivation of hMLH1 and hMSH6 in tumor cells of the microsatellite mutator phenotype. Proc Natl Acad Sci USA 2001, 98:15107-15112.
Dobrovic A., Simpfendorfer D. Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res 1997, 57:3347-3350.
Wei M., Grushko T.A., Dignam J., Hagos F., Nanda R., Sveen L., et al. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res 2005, 65:10692-10699.
Chen Y., Zhou J., Xu Y., Li Z., Wen X., Yao L., et al. BRCA1 promoter methylation associated with poor survival in Chinese patients with sporadic breast cancer. Cancer Sci 2009, 100:1663-1667.
Mirza S., Sharma G., Prasad C.P., Parshad R., Srivastava A., Gupta S.D., et al. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. Life Sci 2007, 81:280-287.
Feng J., Hu L.H., Lu J., Li Y.R., Xie F. Diagnostic value of BRCA1 and p16 gene methylation in sporadic breast cancer. Ai Zheng 2009, 28:436-440.
Matros E., Wang Z.C., Lodeiro G., Miron A., Iglehart J.D., Richardson A.L. BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat 2005, 91:179-186.
Turner N., Tutt A., Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004, 4:814-819.
Butcher Darci T., Rodenhiser David I. Epigenetic inactivation of BRCA1 is associated with aberrant expression of CTCF and DNA methyltransferase (DNMT3B) in some sporadic breast tumors. Eur J Cancer 2007, 43:210-219.
Mancini D.N., Rodenhiser D.I., Ainsworth P.J., O'Malley F.P., Singh S.M., Xing W., et al. CpG methylation within the 5' regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site. Oncogene 1998, 16:1161-1169.
Birgisdottir V., Stefansson O.A., Bodvarsdottir S.K., Hilmarsdottir H., Jonasson J.G., Eyfjord J.E. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res 2006, 8:R38.
Suijkerbuijk K.P., Fackler M.J., Sukumar S., van Gils C.H., van Laar T., van der Wall E., et al. Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer. Ann Oncol 2008, 19:1870-1874.
Troudi W., Uhrhammer N., Romdhane K.B., Sibille C., Amor M.B., Khodjet El Khil H., et al. Complete mutation screening and haplotype characterization of BRCA1 gene in Tunisian patients with familial breast cancer. Cancer Biomark 2008, 4:11-18.
Snell C., Krypuy M., Wong E.M., kConFab investigators, Loughrey M.B., Dobrovic A. BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype. Breast Cancer Res 2008, 10:R12.
Xu X., Gammon M.D., Zhang Y., Cho Y.H., Wetmur J.G., Bradshaw P.T., et al. Gene promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res Treat 2010, 121:685-692.
Ma Y.X., Tomita Y., Fan S., Wu K., Tong Y., Zhao Z., et al. Structural determinants of the BRCA1: estrogen receptor interaction. Oncogene 2006, 24:1831-1846.
Ma Y., Katiyar P., Jones L.P., Fan S., Zhang Y., Furth P.A., et al. The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells. Mol Endocrinol 2006, 20:14-34.
Turner N., Tutt A., Ashworth A. Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol 2005, 5:388-393.
Lord Ashworth C.J. A targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol 2008, 8:363-369.
Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
Miki Y., Katagiri T., Kasumi F., Yoshimoto T., Nakamura Y. Mutation analysis in the BRCA2 gene in primary breast cancers. Nat Genet 1996, 13:245-247.
Lancaster J.M., Wooster R., Mangion J., Phelan C.M., Cochran C., Gumbs C., et al. BRCA2 mutations in primary breast and ovarian cancers. Nat Genet 1996, 13:238-240.
Bièche I., Noguès C., Rivoilan S., Khodja A., Latil A., Lidereau R. Prognostic value of loss of heterozygosity at BRCA2 in human breast carcinoma. Br J Cancer 1997, 76:1416-1418.
van den Berg J., Johannsson O., Håkansson S., Olsson H., Borg A. Allelic loss at chromosome 13q12-q13 is associated with poor prognosis in familial and sporadic breast cancer. Br J Cancer 1996, 74:1615-1619.
Bièche I., Noguès C., Lidereau R. Overexpression of BRCA2 gene in sporadic breast tumours. Oncogene 1999, 18:5232-5238.
Collins N., Wooster R., Stratton M.R. Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers. Br J Cancer 1997, 9:1150-1156.
Rajan J.V., Wang M., Marquis S.T., Chodosh L.A. BRCA2 is co-ordinately regulated with BRCA1 during proliferation and differentiation in mammary epithelial cells. Proc Natl Acad Sci USA 1996, 93:13078-13083.
Xu X., Gammon M.D., Zhang Y., Bestor T.H., Zeisel S.H., Wetmur J.G., et al. BRCA1 promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res Treat 2009, 115:397-404.
Foulkes W.D. BRCA1 BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer 2006, 5:135-142.
Rosell R., Cuello M., Cecere F., Santarpia M., Reguart N., Felip E., et al. Usefulness of predictive tests for cancer treatment. Bull Cancer 2006, 93:E101-E108.
Swisher E.M., Gonzalez R.M., Taniguchi T., Garcia R.L., Walsh T., Goff B.A., et al. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer 2009, 8:48.
Goodheart M.J., Rose S.L., Hattermann-Zogg M., Smith B.J., De Young B.R., Buller R.Z. BRCA2 alteration is important in clear cell carcinoma of the ovary. Clin Genet 2009, 76:161-167.
Silver D.P., Richardson A.L., Eklund A.C., Wang Z.C., Szallasi Z., Li Q., et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010, 28:1145-1153.